References

Abdel-Rahman HM, Al-karamany GS, et al (2002) HIV protease inhibitors: pep-

tidomimetic drugs and future perspectives. Curr Med Chem 9:1905-22 Adams JA, Taylor SS (1992) Energetic limits of phosphotransfer in the catalytic subunit of cAMP-dependent protein kinase as measured by viscosity experiments. Biochemistry 31:8516-22

Alfaro-Lopez J, Yuan W, et al (1998) Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design. J Med Chem 41:2252-60 Ando S, Tsujimura K, et al (1993) Phosphorylation of synthetic vimentin peptides by cdc2 kinase. Biochem Biophys Res Commun 195:837-43 Ando S, Ikuhara T, et al (1997) Role of the pyrrolidine ring of proline in determining the substrate specificity of cdc2 kinase or cdk5. J Biochem [Tokyo] 122:409-14 Beaulieu PL, Cameron DR, et al (1999) Ligands for the tyrosine kinase p56lck SH2 domain: discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements. J Med Chem 42:1757-66 Bohacek RS, Dalgarno DC, et al (2001) X-Ray structure of citrate bound to Src SH2 leads to a high-affinity, bone-targeted Src SH2 inhibitor. J Med Chem 44:660-3 Burke TR Jr, Smyth MS, et al (1993) Preparation of fluoro-4-(phosphonomethyl)-D,L-phenylalanine and hydroxy-4-(phosphonomethyl)-D,L-phenylalanine suitably protected for solid phase synthesis of peptides containing hydrolytically stable analogues of O-phosphotyrosine. J Org Chem 58:1336-40

Burke TR Jr, Smyth MS, et al (1994) Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors. Biochemistry 33:6490-4 Burke TR Jr, Luo J, et al (1999) Monocarboxylic-based phosphotyrosyl mimetics in the design of GRB2 SH2 domain inhibitors. Bioorg Med Chem Lett 9:347-52 Burke TR Jr, Yao ZJ, et al (2001) Phosphoryltyrosyl mimetics in the design of peptide-

based signal transduction inhibitors. Biopolymers 60:32-44 Burke TR Jr, Lee K (2003) Phosphotyrosyl mimetics in the development of signal transduction inhibitors. Acc Chem Res 36:426-33 Burkoth TS, Fafarman AT, et al (2003) Incorporation of unprotected heterocyclic side chains into peptoid oligomers via solid-phase submonomer synthesis. J Am Chem Soc 125:8841-5

Case RD, Piccione E, et al (1994) SH-PTP2/Syp SH2 domain binding specificity is defined by direct interactions with platelet-derived growth factor beta-receptor, epidermal growth factor receptor, and insulin receptor substrate-1-derived phosphopeptides. J Biol Chem 269:10467-74 Cheng HC, Kemp BE, et al (1986) A potent synthetic peptide inhibitor of the cAMP-dependent protein kinase. J Biol Chem 261:989-92 Cole PA, Grace MR, et al (1995) The role of the catalytic base in the protein tyrosine kinase Csk. J Biol Chem 270:22105-8 Combs AP, Kapoor TM, et al (1996) Protein structure-based combinatorial chemistry: discovery of non-peptide binding elements to Src SH3 domain. J Am Chem Soc 118:287-8

Cowburn D, Zheng J, et al (1995) Enhanced affinities and specificities of consolidated lig-ands for the Src homology (SH) 3 and SH2 domains of Abelson protein-tyrosine ki-nase. J Biol Chem 270:26738-41 Csukai M, Mochly-Rosen D (1999) Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation. Pharmacol Res 39:253-9 Cussac D, Vidal M, et al (1999) A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity. FASEB J 13:31-8

Dhanasekaran N, Premkumar Reddy E (1998) Signaling by dual specificity kinases. Oncogene 17:1447-55

Dostmann WR, Taylor MS, et al (2000) Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha inhibit NO-induced cerebral dilation. Proc Natl Acad Sci U S A 97:14772-7 Figliozzi GM, Goldsmith R, et al (1996) Synthesis of N-substituted glycine peptoid libraries. Methods Enzymol 267:437-47 Frank R (2002) The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports—principles and applications. J Immunol Methods 267:13-26 Fry DW, McMichael A, et al (1994) Design of a potent peptide inhibitor of the epidermal growth factor receptor tyrosine kinase utilizing sequences based on the natural phos-phorylation sites of phospholipase C-gamma 1. Peptides 15:951-7 Gao Y, Wu L, et al (2000) Examination of novel non-phosphorus-containing phosphotyrosyl mimetics against protein-tyrosine phosphatase-1B and demonstration of differential affinities toward Grb2 SH2 domains. Bioorg Med Chem Lett 10:923-7 Gilmer T, Rodriguez M, et al (1994) Peptide inhibitors of src SH3-SH2-phosphoprotein interactions. J Biol Chem 269:31711-9 Glass DB, Cheng HC, et al (1989) Primary structural determinants essential for potent inhibition of cAMP-dependent protein kinase by inhibitory peptides corresponding to the active portion of the heat-stable inhibitor protein. J Biol Chem 264:8802-10

Glass DB, Lundquist LJ, et al (1989) Protein kinase inhibitor-(6-22)-amide peptide analogs with standard and nonstandard amino acid substitutions for phenylalanine 10. Inhibition of cAMP-dependent protein kinase. J Biol Chem 264:14579-84 Granier C (2002) Special issue on methods of parallel peptide synthesis and their contributions to deciphering molecular interactions in the immune system. J Immunol Methods 267:1-2

Houghten RA, Blondelle SE, et al (1996) Libraries from libraries: generation and comparison of screening profiles. Mol Divers 2:41-5 Houseman BT, Huh JH, et al (2002) Peptide chips for the quantitative evaluation of protein kinase activity. Nat Biotechnol 20:270-4 Huse M, Kuriyan J (2002) The conformational plasticity of protein kinases. Cell 109:27582

Johnson LN, Lowe ED, et al (1998) The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases. FEBS Lett 430:1-11 Kaiser ET, Mihara H, et al (1989) Peptide and protein synthesis by segment synthesis-

condensation. Science 243:187-92 Kapoor TM, Andreotti AH, et al (1998) Exploring the specificity pockets of two homologous SH3 domains using structure-based, split-pool synthesis and affinity-based selection. J Am Chem Soc 120:23-9 Kim K, Cole PA (1998) Kinetic analysis of a protein tyrosine kinase reaction transition state in the forward and the reverse directions. J Am Chem Soc 120:6851-8 Kole HK, Akamatsu M, et al (1995) Protein-tyrosine phosphatase inhibition by a peptide containing the phosphotyrosyl mimetic, L-O-malonyltyrosine. Biochem Biophys Res Commun 209:817-22

Lam KS, Wu J, et al (1995) Identification and characterization of a novel synthetic pep-tide substrate specific for Src-family protein tyrosine kinases. Int J Pept Protein Res 45:587-92

Lam KS, Liu R, et al (2003) Applications of one-bead one-compound combinatorial libraries and chemical microarrays in signal transduction research. Acc Chem Res 36:370-7

Lashmet PR, Tang K-C, et al (1983) The synthesis of an ATP-gamma-peptidyl ester as a potential probe of c-AMP-dependent protein kinase. Tetrahedron Lett 24:1121-4 Lee TR, Lawrence DS (1999) Acquisition of high-affinity, SH2-targeted ligands via a spatially focused library. J Med Chem 42:784-7 Lee TR, Lawrence DS (2000) SH2-directed ligands of the Lck tyrosine kinase. J Med Chem 43:1173-9

Lee TR, Niu J, et al (1994) Phenol kinase activity of the serine/threonine-specific cAMP-

dependent protein kinase: steric and electronic effects. Biochemistry 33:4245-4250 Lee TR, Niu J, et al (1995a) The extraordinary active site substrate specificity of pp60c-

src. A multiple specificity protein kinase. J Biol Chem 270:5375-80 Lee TR, Till JH, et al (1995b) Precision substrate targeting of protein kinases v-Abl and c-Src. J Biol Chem 270:27022-6 Lee JH, Nandy SK, et al (2004) A highly potent and selective PKCalpha inhibitor generated via combinatorial modification of a peptide scaffold. J Am Chem Soc 126:3394-5 Loog M, Uri A, et al (1999) Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett 9:1447-52 Loog M, Uri A, et al (2000) Bi-substrate analogue ligands for affinity chromatography of protein kinases. FEBS Lett 480:244-8 Lou Q, Leftwich ME, et al (1997) Potent pseudosubstrate-based peptide inhibitors for p60(c-src) protein tyrosine kinase. Cancer Res 57:1877-81

Lukas TJ, Mirzoeva S, et al (1999) Identification of novel classes of protein kinase inhibitors using combinatorial peptide chemistry based on functional genomics knowledge. J Med Chem 42:910-9 Marin O, Meggio F, et al (1999) Tyrosine versus serine/threonine phosphorylation by protein kinase casein kinase-2. A study with peptide substrates derived from im-munophilin Fpr3. J Biol Chem 274:29260-5 McMurray JS, Budde RJ, et al (1998) Cyclic peptides as probes of the substrate binding site of the cytosolic tyrosine kinase, pp60c-src. Arch Biochem Biophys 355:124-30 Medzihradszky D, Chen SL, et al (1994) Solid-phase synthesis of adenosine phosphopep-tides as potential bisubstrate inhibitors of protein kinases. J Am Chem Soc 116:94139

Mitchell RD, Glass DB, et al (1995) Heat-stable inhibitor protein derived peptide substrate analogs: phosphorylation by cAMP-dependent and cGMP-dependent protein kinases. Biochemistry 34:528-34 Morken JP, Kapoor TM, et al (1998) Exploring the leucine-proline binding pocket of the Src SH3 domain using structure-based, split-pool synthesis and affinity selection. J Am Chem Soc 120:30-6 Nguyen JT, Turck CW, et al (1998) Exploiting the basis of proline recognition by SH3 and

WW domains: design of N-substituted inhibitors. Science 282:2088-92 Nguyen JT, Porter M, et al (2000) Improving SH3 domain ligand selectivity using a non-

natural scaffold. Chem Biol 7:463-73 Niu J, Lawrence DS (1997a) L-dopa: a potent nonphosphorylatable tyrosine mimetic for pp60c-src. J Am Chem Soc 119:3844-5 Niu J, Lawrence DS (1997b) Nonphosphorylatable tyrosine surrogates. Implications for protein kinase inhibitor design. J Biol Chem 272:1493-9 O'Brian CA, Ward NE, et al (1990) N-myristyl-Lys-Arg-Thr-Leu-Arg: a novel protein ki-

nase C inhibitor. Biochem Pharmacol 39:49-57 O'Brian CA, Ward NE, et al (1991) A novel N-myristylated synthetic octapeptide inhibits protein kinase C activity and partially reverses murine fibrosarcoma cell resistance to adriamycin. Invest New Drugs 9:169-79 Olivos HJ, Alluri PG, et al (2002) Microwave-assisted solid-phase synthesis of peptoids. Org Lett 4:4057-9

Parang K, Till JH, et al (2001) Mechanism-based design of a protein kinase inhibitor. Nat Struct Biol 8:37-41

Pellicena P, Stowell KR, et al (1998) Enhanced phosphorylation of Src family kinase substrates containing SH2 domain binding sites. J Biol Chem 273:15325-8 Pinna LA, Ruzzene M (1996) How do protein kinases recognize their substrates? Biochim

Biophys Acta 1314:191-225 Pluskey S, Wandless TJ, et al (1995) Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains. J Biol Chem 270:2897-900 Profit AA, Lee TR, et al (1999) Bivalent inhibitors of protein tyrosine kinases. J Am Chem Soc 121:280-3

Profit AA, Lee TR, et al (2001) Molecular rulers: an assessment of distance and spatial relationships of Src tyrosine kinase Sh2 and active site regions. J Biol Chem 276:9446-51

Puius YA, Zhao Y, et al (1997) Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design. Proc Natl Acad Sci USA 94:13420-5

Ramdas L, Obeyesekere NU, et al (1999) N-myristoylation of a peptide substrate for Src converts it into an apparent slow-binding bisubstrate-type inhibitor. J Pept Res 53:569-77

Ricouart A, Gesquiere JC, et al (1991) Design of potent protein kinase inhibitors using the bisubstrate approach. J Med Chem 34:73-8 Ross H, Armstrong CG, et al (2002) A non-radioactive method for the assay of many ser-

ine/threonine-specific protein kinases. Biochem J 366:977-81 Sasaki S, Hashimoto T, et al (1998) Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett 8:1019-22 Scott JD, Fischer EH, et al (1985a) Identification of an inhibitory region of the heat-stable protein inhibitor of the cAMP-dependent protein kinase. Proc Natl Acad Sci USA 82:4379-83

Scott JD, Fischer EH, et al (1985b) Amino acid sequence of the heat-stable inhibitor of the cAMP-dependent protein kinase from rabbit skeletal muscle. Proc Natl Acad Sci USA 82:5732-6

Scott JD, Glaccum MB, et al (1986) Primary-structure requirements for inhibition by the heat-stable inhibitor of the cAMP-dependent protein kinase. Proc Natl Acad Sci USA 83:1613-6

Scott JK, Smith GP (1990) Searching for peptide ligands with an epitope library. Science 249:386-90

Shen K, Keng YF, et al (2001) Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J Biol Chem 276:47311-47319 Shoelson SE, White MF, et al (1989) Nonphosphorylatable substrate analogs selectively block autophosphorylation and activation of the insulin receptor, epidermal growth factor receptor, and pp60v-src kinases. J Biol Chem 264:7831-6 Smith GP, Scott JK (1993) Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol 217:228-57 Smothers JF, Henikoff S, et al (2002) Tech.Sight. Phage display. Affinity selection from biological libraries. Science 298:621-2 Smyth MS, Ford H, et al (1992) A general method for the preparation of benzylic alpha, alpha-difluorophosphonic acids; non-hydrolyzable mimetics of phosphotyrosine. Tetrahedron Lett 33:4137-40 Songyang Z, Shoelson SE, et al (1993) SH2 domains recognize specific phosphopeptide sequences. Cell 72:767-78 Songyang Z, Blechner S, et al (1994) Use of an oriented peptide library to determine the optimal substrates of protein kinases. Curr Biol 4:973-82 Songyang Z, Cantley LC (1998) The use of peptide library for the determination of kinase peptide substrates. Methods Mol Biol 87:87-98 Stankovic CJ, Surendranc N, et al (1997) The role of 4-phosphonodifluoromethyl- and 4-phosphonon-phenylalanine in the selectivity and cellular uptake of SH2 domain ligands. Bioorg Med Chem Lett 7:1909-14 Stanyon CA, Bernard O (1999) LIM-kinase1. Int J Biochem Cell Biol 31:389-94 Sugimoto S, Wandless TJ, et al (1994) Activation of the SH2-containing protein tyrosine phosphatase, SH-PTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1. J Biol Chem 269:13614-22 Tong L, Warren TC, et al (1996) Crystal structures of the human p56lck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution. J Mol Biol 256:601-10

Tong L, Warren TC, et al (1998) Carboxymethyl-phenylalanine as a replacement for phos-photyrosine in SH2 domain binding. J Biol Chem 273:20238-42

Uri A, Raidaru G, et al (2002) Identification of the ability of highly charged nanomolar inhibitors of protein kinases to cross plasma membranes and carry a protein into cells. Bioorg Med Chem Lett 12:2117-20 Van Patten SM, Fletcher WH, et al (1986) The inhibitor protein of the cAMP-dependent protein kinase-catalytic subunit interaction. Parameters of complex formation. J Biol Chem 261:5514-23

Viht K, Padari K, et al (2003) Liquid-phase synthesis of a pegylated adenosine-oligoargi-nine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett 13:3035-9 Wang W, Ramdas L, et al (2000) Cyclic peptides incorporating 4-carboxyphenylalanine and phosphotyrosine are potent inhibitors of pp60(c-)(src). Biochemistry 39:5221-8 Ward NE, O'Brian AA (1993) Inhibition of protein kinase C by N-myristoylated peptide substrate analogs. Biochemistry 32:11903-9 Whitehouse S, Walsh DA (1983) Mg X ATP2-dependent interaction of the inhibitor protein of the cAMP-dependent protein kinase with the catalytic subunit. J Biol Chem 258:3682-92

Whitehouse S, Feramisco JR, et al (1983) Studies on the kinetic mechanism of the catalytic subunit of the cAMP-dependent protein kinase. J Biol Chem 258:3693-701 Wong TW, Goldberg AR (1984) Kinetics and mechanism of angiotensin phosphorylation by the transforming gene product of Rous sarcoma virus. J Biol Chem 259:3127-31 Wood J, Koszelak M, et al (1998) A caged protein kinase inhibitor. J Am Chem Soc 120:7145-7146

Wood JS, Yan X, et al (1996) Precision substrate targeting of protein kinases. The cGMP-

and cAMP-dependent protein kinases. J Biol Chem 271:174-9 Wu J, Ma QN, et al (1994) Identifying substrate motifs of protein kinases by a random library approach. Biochemistry 33:14825-33 Wu J, Phan H, et al (1996) Development of a selective pseudosubstrate-based peptide inhibitor of p60c-src. Lett Pept Sci 3:309-16 Xu Q, Zheng J, et al (1999) Flexibility of interdomain contacts revealed by topological isomers of bivalent consolidated ligands to the dual Src homology domain SH(32) of abelson. Biochemistry 38:3491-7 Yan X, Curley K, et al (2000) The specificity of the protein kinase C alpha, betaII and gamma isoforms as assessed by an unnatural alcohol-appended peptide library. Bio-chem J 349 Pt 3:709-15 Ye B, Akamatsu M, et al (1995) L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides. J Med Chem 38:4270-5

Yeh RH, Lee TR, et al (2001) From consensus sequence peptide to high affinity ligand, a library scan strategy. J Biol Chem 276:12235-40 Yuan CJ, Jakes S, et al (1990) A rationale for the design of an inhibitor of tyrosyl kinase.

J Biol Chem 265:16205-9 Zaliani A, Pinori M, et al (1998) The interaction of myristylated peptides with the catalytic domain of protein kinase C revealed by their sequence palindromy and the identification of a myristyl binding site. Protein Eng 11:803-10 Zhu H, Klemic JF, et al (2000) Analysis of yeast protein kinases using protein chips. Nat Genet 26:283-9

Part II

Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases

HEP (2005) 167:47-64 © Springer-Verlag 2005

Supplements For Diabetics

Supplements For Diabetics

All you need is a proper diet of fresh fruits and vegetables and get plenty of exercise and you'll be fine. Ever heard those words from your doctor? If that's all heshe recommends then you're missing out an important ingredient for health that he's not telling you. Fact is that you can adhere to the strictest diet, watch everything you eat and get the exercise of amarathon runner and still come down with diabetic complications. Diet, exercise and standard drug treatments simply aren't enough to help keep your diabetes under control.

Get My Free Ebook


Post a comment